Company intelligence / Profile preview

BioCis Pharma

Ownership: Private
Development stage: Phase 2

Overview

BioCis Pharma was a Finnish clinical-stage drug development company focused on unmet needs in inflammation, allergy, dermatology, ophthalmology and oncology. Its lead asset was ProtoDynamic Therapy/cis-UCA-based products. The company had ongoing Phase IIa trials in atopic dermatitis and psoriasis and a Phase I trial in non-muscle invasive bladder cancer before merging with Lx Therapies to form Laurantis Pharma Oy around late 2010/early 2011. Key results from these studies were expected by late 2009 or early the following year.

Therapeutic areas: OphthalmologyOncologyDermatologyNephrology
Modalities: Small moleculesLocally acting anti-inflammatory and anti-proliferative agents (e.g., cis-UCA)
Industry: Biotech

Drug pipeline

1 asset

ProtoCure

Phase 2

Indications: Psoriasis, Atopic dermatitis

Partnerships

Inveni Capital and Helsinki University Funds invested during the merger forming Laurantis.

Beyond the preview

Go deeper on BioCis Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioCis Pharma.

Explore the full profile